Molecular structure of Tetrandrine, CAS Number: 518-34-3
Tetrandrine (CAS 518-34-3)
See product citations (9)
Alternate Names:
Fanchinine; Hanfangchin A; (1β)-6,6,7,12-Tetramethoxy-2,2-dimethyl-berbaman
Application:
Tetrandrine is a calcium channel protein inhibitor
CAS Number:
518-34-3
Purity:
≥98%
Molecular Weight:
622.75
Molecular Formula:
C38H42N2O6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Tetrandrine is a calcium channel protein inhibitor. Tetrandrine blocks the L-type (IC50= 0.3-8 µM) and T-type (IC50= 2.5-20 µM) calcium channels. It is also a potent blocker of the Ca2+-activated K+ channel (Kd= 0.2 µM). One of the primary mechanisms of action of tetrandrine is its ability to inhibit the release of inflammatory mediators such as histamine and cytokines.
Tetrandrine (CAS 518-34-3) References
- The Potential of Tetrandrine against Gliomas. | Chen, Y. and Tseng, SH. 2010. Anticancer Agents Med Chem. 10: 534-42. PMID: 20879981
- Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. | Liu, T., et al. 2016. Oncotarget. 7: 40800-40815. PMID: 27027348
- [Research development on modern pharmacological effect of tetrandrine]. | Xi, Y., et al. 2020. Zhongguo Zhong Yao Za Zhi. 45: 20-28. PMID: 32237407
- Tetrandrine: a review of its anticancer potentials, clinical settings, pharmacokinetics and drug delivery systems. | Luan, F., et al. 2020. J Pharm Pharmacol. 72: 1491-1512. PMID: 32696989
- Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases. | Xu, W., et al. 2021. Pharmacol Ther. 217: 107659. PMID: 32800789
- Tetrandrine attenuates intestinal epithelial barrier defects caused by colitis through promoting the expression of Occludin via the AhR-miR-429 pathway. | Chu, Y., et al. 2021. FASEB J. 35: e21502. PMID: 33811696
- Mechanism of Tetrandrine Against Endometrial Cancer Based on Network Pharmacology. | Shang, W., et al. 2021. Drug Des Devel Ther. 15: 2907-2919. PMID: 34262258
- Tetrandrine alleviates silicosis by inhibiting canonical and non-canonical NLRP3 inflammasome activation in lung macrophages. | Song, MY., et al. 2022. Acta Pharmacol Sin. 43: 1274-1284. PMID: 34417574
- Autophagy and cancer: Can tetrandrine be a potent anticancer drug in the near future? | Bhagya, N. and Chandrashekar, KR. 2022. Biomed Pharmacother. 148: 112727. PMID: 35219119
- Tetrandrine Inhibits Skeletal Muscle Differentiation by Blocking Autophagic Flux. | Li, J., et al. 2022. Int J Mol Sci. 23: PMID: 35897724
- Tetrandrine: a new ligand to block voltage-dependent Ca2+ and Ca(+)-activated K+ channels. | Wang, G. and Lemos, JR. 1995. Life Sci. 56: 295-306. PMID: 7837929
- Phenotypic alteration of a human BK (hSlo) channel by hSlobeta subunit coexpression: changes in blocker sensitivity, activation/relaxation and inactivation kinetics, and protein kinase A modulation. | Dworetzky, SI., et al. 1996. J Neurosci. 16: 4543-50. PMID: 8764643
- Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. | Kwan, CY. 1995. Clin Exp Pharmacol Physiol Suppl. 22: S297-9. PMID: 9072399
Inhibitor of:
ABC-1, ATP13A5, C. abortus LPS, Calcium Channel Protein, CCL (C-C motif chemokine ligand), E-cadherin, Endo180, GMF-β, Mast Cell Protease 1, MCP-1, Olfr936, RAMP1, Rap1GAP, SLC5 (solute carrier family 5; SLC5A), SNAP 23, SNT-2, SPARC, T-type Ca++ CP α1I, T-type calcium channel α1G, T-type calcium channel α1I, TMEM150B, TMEM80, TPCN2, and VAT1.Activator of:
COX4, and T-type calcium channel α1I.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tetrandrine, 100 mg | sc-201492 | 100 mg | $55.00 | |||
Tetrandrine, 250 mg | sc-201492A | 250 mg | $98.00 |